Tag: Trametinib [Mekinist]

By Posted on Posted in Allelic Variant, New Drug Approval, New Indication Approval, Personalized Medicine, Regulatory Announcement, Targeted Therapy, Thasso Post, Theragenomic Medicine Tagged with , , , , , , , , ,

  May 05, 2018 – The American Food and Drug Administration (FDA) just approved the combination of Dabrafenib (Tafinlar)/Trametinib (Mekinist) to be administered together for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has …

Dabrafenib/Trametinib-Combo approved for BRAF-positive anaplastic thyroid cancer Read more »

By Posted on Posted in Personalized Medicine, Targeted Therapy, Thasso Post, Theragenomics Tagged with , , , , , ,

April 30, 2014 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Mekinist (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E mutation. Mekinist …

European Medicines Agency (EMA) recommends approval of Trametinib [Mekinist] for the treatment of melanoma with a BRAF V600E mutation Read more »

By Posted on Posted in Allelische Variante, Genetic Predisposition, New Drug Approval, Personalized Medicine, Pharmacogenetics, Thasso Post Tagged with , , , , , , ,

May 30, 2013 – From a Medscape News Release we learn today that two new drugs have been approved by the US Food and Drug Administration (FDA) for use in certain patients with metastatic or unresectable melanoma, along with a …

Dabrafenib [Tafinalar] and Trametinib [Mekinist] Approved for BRAF V600 Mutated Metastatic Melanoma Read more »